Chemi-Verse™ CDK17/Cyclin Y Kinase Assay Kit

Catalog #
78885
$750 *
Size: 96 reactions
Qty
*US Pricing only. For international pricing, please contact your local distributor.
Purchase
Description

The Chemi-Verse™ CDK17/Cyclin Y Kinase Assay is a luminescent assay designed to measure CDK17 (cyclin-dependent kinase 17)/Cyclin Y kinase activity for screening and profiling applications using ADP-Glo™ as a detection reagent. The assay kit comes in a convenient 96-well format, with enough purified recombinant complex of CDK17/Cyclin Y, kinase substrate, ATP, and kinase assay buffer for 100 enzyme reactions.

Synonyms
Cyclin-dependent kinase 17, Cell division protein kinase 17, PCTAIRE-motif protein kinase 2, Serine/threonine-protein kinase PCTAIRE-2, PCTAIRE2, PCTK2, Cyclin-Y, Cyc-Y, Cyclin box protein 1, Cyclin fold protein 1, cyclin-X, CCNY, C10orf9, CBCP1, CFP1, CD
Product Info
Storage and Usage
Citations
Materials Required But Not Supplied
  • ADP-Glo™ Kinase Assay (Promega #V6930)
  • DTT (Dithiothreitol), 1M, optional
  • Microplate reader capable of reading luminescence
  • Adjustable micropipettor and sterile tips
  • 30°C incubator 
Format
Catalog # Name Amount  Storage
100606 CDK17/Cyclin Y, GST-Tag Recombinant* 5 µg -80°C
79334 5x Kinase Assay Buffer 1  1.5 ml -20°C
79686 500 µM ATP 50 µl -20°C
79604 5x CDK Substrate Peptide 2 125 µl -20°C
79696 White 96-well plate 1 Room Temp

*The concentration of the protein is lot-specific and will be indicated on the tube.

UniProt #
CDK17: Q00537; Cyclin Y: Q8ND76
Background

CDK17 (cyclin dependent kinase 17, also known as PCTK2) is a member of the cyclin-dependent protein kinase family involved in cell cycle regulation, transcription and splicing.  CDK associates with cyclins, which induce a conformational change that results in a dramatic increase of the kinase activity. Cyclin levels vary during the cell cycle, which allow cyclins to regulate CDK activity in the cell. Dissociation of the complex returns CDK to its basal activity, and CDK is degraded by ubiquitin mediated proteolysis. Lack of regulation in cell cycle can result in apoptosis and finally in cancer, neurodegenerative diseases (Alzheimer’s or Parkinson disease) and cardiovascular complications (stroke). The understanding of the mechanisms involved in cell cycle regulation, and its control via the use of small molecule inhibitors will open new therapeutic avenues for the treatment of cancer and neurodegenerative diseases.